tried satiety for 2 weeks. here is what happened.
tried satiety for 2 weeks. here is what happened. I have gone back and forth on this for months.
The relevant figures are 2 weeks, and they come from the same log I have kept the whole time.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Is there any independent purity data on this compound that you have seen?
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
independent purity data on this compound is thin
This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Agreed, and the combination arms are where the interesting numbers actually live.
nothing here is approved as a standalone product and research material is not for human use
phase 3 data will change most of what gets said here
do not assume the dosing intuitions from the GLP-1 boards transfer
How many separate lots has anyone here tested?
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
Monotherapy arm or combination arm?
nausea profile in the combination trials is the thing to read carefully
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
the monotherapy numbers are modest and that is not the point
Which receptor family are you attributing that effect to?